---
title: "Leap Therap (LPTX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LPTX.US.md"
symbol: "LPTX.US"
name: "Leap Therap"
industry: "Biotechnology"
---

# Leap Therap (LPTX.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |

## Company Profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.76 | 254/604 | - | - | - |
| PB | 20.31 | 419/604 | 20.31 | 2.05 | 0.47 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.05 |
| Highest Target | 3.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/LPTX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LPTX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LPTX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.